Archived COVID-19 Vaccination Schedules
This web page is archived for historical purposes and is no longer being updated. Please go to CDC Home or use the A-Z Index or Search for more recent information.
The August 22, 2022 COVID-19 vaccination schedules below were the most recent revision to the schedules prior to the initial authorization of bivalent mRNA COVID-19 boosters on August 31, 2022. They should be used for historical and research purposes only.
CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States should be consulted for current COVID-19 vaccination schedules and guidance. The Advisory Committee on Immunization Practices (ACIP) COVID-19 vaccine recommendations provide additional information.
6 months through 11 years
| Manufacturer | Age group |
Total number of doses recommended | Number of primary doses* | Number of booster doses† | Interval between 1st and 2nd dose‡ | Interval between 2nd and 3rd dose | Interval between 3rd and 4th dose |
|---|---|---|---|---|---|---|---|
| Moderna | 6 months–5 years | 2 | 2 | NA | 4–8 weeks | NA | NA |
| Moderna | 6–11 years | 2 | 2 | NA | 4–8 weeks | NA | NA |
| Pfizer-BioNTech | 6 months–4 years | 3 | 3 | NA | 3–8 weeks | At least 8 weeks | NA |
| Pfizer-BioNTech | 5–11 years | 3 | 2 | 1 | 3–8 weeks | At least 5 months | NA |
12 through 17 years
| Manufacturer | Age group |
Total number of doses recommended | Number of primary doses* | Number of booster doses† | Interval between 1st and 2nd dose‡ | Interval between 2nd and 3rd dose | Interval between 3rd and 4th dose |
|---|---|---|---|---|---|---|---|
| Moderna | 12–17 years | 2 | 2 | NA | 4–8 weeks | NA | NA |
| Novavax | 12–17 years | 2 | 2 | NA | 3–8 weeks | NA | NA |
| Pfizer-BioNTech | 12–17 years | 3 | 2 | 1 | 3–8 weeks | At least 5 months | NA |
18 years and older
| Manufacturer | Age group |
Total number of doses recommended | Number of primary doses* | Number of booster doses† | Interval between 1st and 2nd dose‡ | Interval between 2nd and 3rd dose | Interval between 3rd and 4th dose |
|---|---|---|---|---|---|---|---|
| Moderna | 18–49 years | 3 | 2 | 1 | 4–8 weeks | At least 5 months | NA |
| Moderna | 50 years and older | 4 | 2 | 2 | 4–8 weeks | At least 5 months | At least 4 months |
| Novavax | 18 years and older | 2 | 2 | NA | 3–8 weeks | NA | NA |
| Pfizer-BioNTech | 18–49 years | 3 | 2 | 1 | 3–8 weeks | At least 5 months | NA |
| Pfizer-BioNTech | 50 years and older | 4 | 2 | 2 | 3–8 weeks | At least 5 months | At least 4 months |
| Janssen | 18–49 years | 2 | 1 | 1§ | At least 2 months | NA | NA |
| Janssen | 50 years and older | 3 | 1 | 2 | At least 2 months | At least 4 months | NA |
Footnotes
*For primary series vaccination, Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are recommended. Janssen COVID-19 Vaccine should only be used in limited situations.
†For booster vaccination, Moderna and Pfizer-BioNTech are recommended and must be used for the second booster dose. Janssen COVID-19 Vaccine should only be used in limited situations. Currently, a booster dose using any COVID-19 vaccine is not authorized for people ages 6–17 years who receive a Moderna primary series or people ages 12 years and older who receive a Novavax primary series.
‡An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis/pericarditis associated with these vaccines. A shorter interval (3 weeks for Novavax and Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 Community Levels or an individual’s higher risk of severe disease.
§People ages 18–49 years who received Janssen COVID-19 Vaccine as both their primary dose and first booster dose may receive a second booster dose using an mRNA vaccine at least 4 months after the first booster dose.
6 months through 11 years
| Manufacturer | Age group |
Total number of doses recommended | Number of primary doses* | Number of booster doses† | Interval between 1st and 2nd dose | Interval between 2nd and 3rd dose | Interval between 3rd and 4th dose | Interval between 4th and 5th dose |
|---|---|---|---|---|---|---|---|---|
| Moderna | 6 months–5 years | 3 | 3 | NA | 4 weeks | At least 4 weeks | NA | NA |
| Moderna | 6–11 years | 3 | 3 | NA | 4 weeks | At least 4 weeks | NA | NA |
| Pfizer-BioNTech | 6 months–4 years | 3 | 3 | NA | 3 weeks | At least 8 weeks | NA | NA |
| Pfizer-BioNTech | 5–11 years | 4 | 3 | 1 | 3 weeks | At least 4 weeks | At least 3 months | NA |
12 through 17 years
| Manufacturer | Age group |
Total number of doses recommended | Number of primary doses* | Number of booster doses† | Interval between 1st and 2nd dose | Interval between 2nd and 3rd dose | Interval between 3rd and 4th dose | Interval between 4th and 5th dose |
|---|---|---|---|---|---|---|---|---|
| Moderna | 12–17 years | 3 | 3 | NA | 4 weeks | At least 4 weeks | NA | NA |
| Novavax | 12–17 years | 2 | 2 | NA | 3 weeks | NA | NA | NA |
| Pfizer-BioNTech | 12–17 years | 5 | 3 | 2 | 3 weeks | At least 4 weeks | At least 3 months | At least 4 months |
18 years and older
| Manufacturer | Age group |
Total number of doses recommended | Number of primary doses* | Number of booster doses† | Interval between 1st and 2nd dose | Interval between 2nd and 3rd dose | Interval between 3rd and 4th dose | Interval between 4th and 5th dose |
|---|---|---|---|---|---|---|---|---|
| Moderna | 18 years and older | 5 | 3 | 2 | 4 weeks | At least 4 weeks | At least 3 months | At least 4 months |
| Novavax | 18 years and older | 2 | 2 | NA | 3 weeks | NA | NA | NA |
| Pfizer-BioNTech | 18 years and older | 5 | 3 | 2 | 3 weeks | At least 4 weeks | At least 3 months | At least 4 months |
| Janssen | 18 years and older | 4 | 2 (1 Janssen, followed by 1 mRNA) |
2 | At least 4 weeks | At least 2 months | At least 4 months | NA |
Footnotes
*For primary series vaccination, Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are recommended; Janssen COVID-19 Vaccine should only be used in limited situations.
†For booster vaccination, Moderna and Pfizer-BioNTech are recommended and must be used for the second booster dose. Janssen COVID-19 Vaccine should only be used in limited situations. Currently, a booster dose using any COVID-19 vaccine is not authorized for people ages 6–17 years who receive a Moderna primary series or people ages 18 years and older who receive a Novavax primary series.